Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	OMB APPROVAL									
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Arkowitz David						2. Issuer Name and Ticker or Trading Symbol Seres Therapeutics, Inc. [MCRB]								check all appli Directo Officer	ationship of Reporting k all applicable) Director Officer (give title		10% Ow Other (s	/ner			
									3. Date of Earliest Transaction (Month/Day/Year) 02/03/2023							Chief Financial Officer					
(Street) CAMBR (City)			02139 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)							ne) X Form f	′ I								
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
Date				2. Transa Date (Month/D	Execution Date,		, Transaction Disposed Code (Instr. 5)		ities Acquired (A) d Of (D) (Instr. 3,		Benefici	es ally Following	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)						
							Code	v	Amount	(A) or (D) Pr		Transac	Transaction(s) (Instr. 3 and 4)			(IIISti. 4)					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) Execution Date, if any			ate, T	ransaction of ode (Instr. Derivative			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		Derivative Security	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)						
				c	ode	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amoun or Numbe of Shares								
Restricted Stock Units	(1)	02/03/2023			A		42,500		(2)		(2)	Common Stock	42,50	\$0.00	42,500		D				
Stock Option (Right to Buy)	\$5.5	02/03/2023			A		85,000		(3)	0	02/02/2033	Common Stock	85,00	\$0.00	85,000		D				

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- 2. The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments
- 3. The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

Remarks:

/s/ Thomas J. DesRosier, attorney-in-fact for David 02/07/2023 **Arkowitz**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.